Quantcast
Home > Quotes > IDRA
IDRA

Idera Pharmaceuticals, Inc. Common Stock (IDRA) Quote & Summary Data

$8.51
*  
1.12
15.16%
Get IDRA Alerts
*Delayed - data as of Aug. 14, 2018  -  Find a broker to begin trading IDRA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    IDRA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
17
Today's High / Low
$ 8.59 / $ 7.15
Share Volume
2,746,149
50 Day Avg. Daily Volume
378,318
Previous Close
$ 7.39
52 Week High / Low
$ 22.96 / $ 5.20
Market Cap
3,611,950
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.37

Special Dividend Data

Special Dividend
N/A
Special Dividend Date
Jul. 30, 2018
Special Dividend Payment Date
N/A

Intraday Chart

Shares Traded

Share Volume:
2,746,149
50 Day Avg. Daily Volume:
378,318

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.83

Trading Range

The current last sale of $8.51 is 63.65% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.59 $ 22.96
 Low: $ 7.15 $ 5.20

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. We use two distinct proprietary drug discovery technology platforms to design and develop drug candidates: our Toll-like receptor, or TLR, targeting technology and our nucleic acid chemistry technology (formerly referred to as our third generation antisense, or 3GA, technology). We developed these platforms based on our scientific expertise and pioneering work with synthetic oligonucleotides as therapeutic agents. Using our TLR targeting technology, we design synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. In addition, using our nucleic acid chemistry technology, we are developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes.  ... More ...  


Risk Grade

Where does IDRA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 7.45
Open Date:
Aug. 14, 2018
Close Price:
$ 8.51
Close Date:
Aug. 14, 2018

Consensus Recommendation

Analyst Info